跳至主要内容
临床试验/TCTR20230606002
TCTR20230606002已完成2 期

A study of role of trimethoprim-sulfamethoxazole in opportunistic infection prevention in lupus patients taking low-level immunosuppressive treatment

Mahidol university0 个研究点目标入组 138 人开始时间: 2023年6月6日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
138

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1.Lupus patients diagnosed by 2019 EULAR/ACR Criteria for SLE
  • 2.Taking low level immunosuppressive treatment

排除标准

  • 1.History of TMP/SMX allergy
  • 2.Need for TMP/SMX treatment
  • 3.Overlap syndrome
  • 4.HIV infection
  • 5.Pregnancy
  • 6. Cancer patient
  • 7.Transplant patient
  • 8.History of TMP/SMX sensitive opportunistic infections within 6 months
  • 9.History of pulse immunosuppressive treatment within 6 months
  • 10.History of CMV infection or CMV disease within 3 months
  • 11.Received pentamidine or dapsone for any indication prior to enrollment

研究者

相似试验